赛诺医疗：子公司产品获欧盟CE MDR认证

Core Viewpoint - The announcement indicates that the subsidiary of the company, Sainuo Shenchang, has received CE MDR certification for its Ghunter intracranial thrombectomy stent, which is a significant milestone for market entry in the EU [1] Group 1: Product Development and Certification - The Ghunter stent was granted a medical device registration certificate by the National Medical Products Administration of China in April 2023 [1] - The certification from the EU is valid from February 18, 2026, to February 1, 2031, indicating a long-term approval for the product [1] - The product is designed for acute ischemic conditions and features advantages such as full imaging design and curling design [1] Group 2: Market Impact and Future Considerations - The CE certification allows the product to meet the conditions for market entry in the EU, which is expected to positively influence product promotion and sales, as well as enhance the company's competitiveness [1] - However, further local registration is required, and sales will be influenced by various factors, making the specific impact on performance unpredictable [1]